Article
Ablation of hepatocyte derived-FGL1 does not aggravate metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma
2024-12-23
Abstract excerpt
Metabolic dysfunction-associated steatotic liver disease (MASLD) begins with simple steatosis, which can progress to hepatocellular carcinoma (HCC). The pathogenesis of MASLD alters the secretion of hepatokines such as fibrinogen-like 1 (FGL1), a candidate mediator of liver steatosis and hyperglycemia. To investigate the contribution of FGL1 to liver diseases, we compared wild-type mice to mice with hepatocyte-spe...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a047aeaf-3b88-58b4-9de7-40f9d8707370
- DOI
- 10.1101/2024.12.23.628701
